Immunohistochemical evaluation of ALK expression in non-small cell lung cancer and its association with clinicopathological parameters

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 450

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ACPLMED20_030

تاریخ نمایه سازی: 29 تیر 1398

چکیده مقاله:

Introduction Approximately 4% of Non- small cell lung cancers (NSCLC ) cases, especially in non-smoker younger patients with lung adenocarcinoma, have ALK gene mutations. Adenocarcinomas with this genetic mutation are very sensitive to the treatment of tyrosine kinase inhibitors and have a good therapeutic prognosis. Currently, NSCLC patients who are ALK-positive, have a different treatment with other NSCLC cases. Objectives & ( hypothesis OR questions) The aim of this study was to assess ALK expression in NSCLC and its relationship with clinicopathologic factors. This marker can be used as an important parameter in determining the prognosis of patients at the time of initial diagnosis. Moreover, with a better understanding of the molecular biology of ALK-positive tumor cells, more effective therapies can be used to treat this deadly tumors.Materials & Methods This study was performed on 93 patients, who underwent bronchoscopy and/or surgery in a referral Hospital. Clinicopathologic information and pathology reports of the patients were extracted from the hospital records and pathology archive. After selecting the appropriate blocks and slides, immunohistochemical staining was performed and a phone call was made to determine the survival.Results Out of 93 patients, 68.4% were males and 31.6% were females. 49.4% of patients had SCC, 49.4% AC and 1.3% LCC. Half of the patients underwent surgery and 71.2% of the candidates received chemotherapy. The Intensity of ALK IHC was as negative (81.7%), weak (6.5%), moderate (7.5%) and severe (4.3%). Tumor percentage was calculated in the five groups of less than 1 % (81.7%), 25-1 (7.5%), 50-26 (7.5%), 75-51 (3.2%), and 100-76 (0%). Thus, 81.7% were the low score, 17.2% the medium score, and 1.1% was the high score. There was no significant relationship between age, sex, type of carcinoma, type of treatment and score. Survival analysis did not show a significant relationship.Conclusion In this study, which was conducted at a referral center in the northeast of the country, the majority of patients were in the low score category and there was no significant relationship between ALK expression and survival.

کلیدواژه ها:

Non-Small Cell Lung Cancer- ALK- Immunohistochemistry

نویسندگان

Masoumeh Gharib

Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Amirhossein Jafarian

Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Sahar Bagheri

Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Adel Shahidi

Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran